Dr Reddy's to commercialize two Torrent drugs in Russia
Dr Reddy's Laboratories has concluded an agreement with fellow Indian firm Torrent Pharmaceuticals for the exclusive commercialization of two of its brands in Russia, These are Torrent's antihypertensives Listril (lisinopril) and Listril Plus, both of which have already been registered in Russia. This is the second deal that Dr Reddy's has concluded with Torrent for this market. It previously licensed Omez (omeprazole plus domperidone), used for the treatment of gastrointestinal diseases. The product will be launched in Ukraine and Kazakhstan shortly, followed by Russia and Belarus. Financial terms of the arrangement were not disclosed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze